Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
企業コードEVO
会社名Evotec SE
上場日Oct 11, 1999
設立日2019
最高経営責任者「CEO」Dr. Christian Wojczewski
従業員数4827
証券種類Ordinary Share
決算期末Oct 11
本社所在地Essener Bogen 7
都市HAMBURG
証券取引所OMX Nordic Exchange Stockholm AB - cash
国Germany
郵便番号22419
電話番号4940560810
ウェブサイトhttps://www.evotec.com/
企業コードEVO
上場日Oct 11, 1999
設立日2019
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし